Безопасность и риск фармакотерапии (Feb 2018)
SGLT2 inhibitors: control of glycemia and nephroprotection properties
Abstract
Recently were appeared a fundamentally new insulin-independent approach to the treatment of type 2 diabetes - reduce blood glucose levels by inhibiting proteins co-transporters SGLT2 (sodium glucose transporter) in the proximal tubules of the kidneys, which are responsible for the reabsorption of glucose. Inhibitors SGLT2 co-transporters is effective either as monotherapy or in combination with other antidiabetic drugs. Thus, according to the results of randomized controlled trials, therapy with this class of drugs was well tolerated. The incidence of hypoglycemia was not statistically different from the incidence of hypoglycemia in the placebo group. On the background of therapy was observed a stable decrease in body weight in patients with type 2 diabetes. Therapy with all drugs of a class of SGLT2 inhibitors was accompanied by a decrease in blood pressure and body weight. This class of drugs could potentially play an important role in the early stages of development of diabetic nephropathy, with potential nephrorotective effect, working on the level of reduction intraglomerular pressure of a single nephron. Insulin-independent mechanism of action and low risk of hypoglycaemia makes the SGLT2 inhibitors effective and safe addition to existing methods of control glycemia in patients with type 2 diabetes.
